Previous 10 | Next 10 |
home / stock / ocgn / ocgn articles
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action law...
ATLANTA, April 12, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces tha...
LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action law...
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons an...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Com...
Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 7.7% to $1.97 during Monday’s session after the company announced U.S. FDA clearance of...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...